The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Oramed Pharmaceuticals Inc. shares valued at $8,398 were purchased by Mayer Arie on Apr 04. At $2.21 per share, Mayer Arie acquired 3,800 shares. The insider’s holdings grew to 26,809 shares worth approximately $98120.94 following the completion of this transaction.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Also, Mayer Arie purchased 5,009 shares, netting a total of over 11,120 in proceeds. Following the buying of shares at $2.22 each, the insider now holds 23,009 shares.
Before that, KIDRON NADAV had added 26,000 shares to its account. In a trade valued at $53,014, the President and CEO bought Oramed Pharmaceuticals Inc. shares for $2.04 each. Upon closing the transaction, the insider’s holdings increased to 26,000 shares, worth approximately $0.46 million.
Analyzing ORMP Stock Performance
On Thursday, Oramed Pharmaceuticals Inc. [NASDAQ: ORMP] plunged -18.12% to $3.66. The stock’s lowest price that day was $3.61, but it reached a high of $4.51 in the same session. During the last five days, there has been a drop of approximately -10.95%. Over the course of the year, Oramed Pharmaceuticals Inc. shares have dropped approximately -69.58%. Shares of the company reached a 52-week high of $13.73 on 01/05/23 and a 52-week low of $1.81 on 01/19/23. A 50-day SMA is recorded $2.65, while a 200-day SMA reached $5.48. Nevertheless, trading volume fell to 1.42 million shares from 0.59 million shares the previous day.
Support And Resistance Levels for Oramed Pharmaceuticals Inc. (ORMP)
According to the 24-hour chart, there is a support level at 3.34, which, if violated, would cause prices to drop to 3.03. In the upper region, resistance lies at 4.24. The next price resistance is at 4.83. RSI (Relative Strength Index) is 57.35 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.57, which suggests the price will decrease in the coming days. Percent R is at 62.72%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Oramed Pharmaceuticals Inc. subject to short interest?
Stocks of Oramed Pharmaceuticals Inc. saw a sharp steep in short interest on May 14, 2023 dropping by -0.29 million shares to 0.49 million. Data from Yahoo Finance shows that the short interest on Apr 13, 2023 was 0.78 million shares. A decline of -60.63% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 0.36 of the overall float, the days-to-cover ratio (short ratio) decline to 0.36.
Which companies own the most shares of Oramed Pharmaceuticals Inc. (ORMP)?
According to BML Capital Management LLC filings, the company currently owns 1,355,925 shares, which is about 3.41% of the total ORMP shares outstanding. Two Sigma Advisers LP acquire a 76.62% interest valued at $1.01 million while Jess S. Morgan & Co., Inc. purchased a 51,100 stake. A total of -4,071 shares of Oramed Pharmaceuticals Inc. were bought by Morgan Stanley & Co. LLC during the quarter, and 168,935 were bought by Migdal Mutual Funds Ltd. In its current portfolio, JPMorgan Securities LLC holds 174,122 shares valued at $0.4 million.